证券代码：600062 证券简称：华润双鹤 公告编号：临 2026-002 华润双鹤药业股份有限公司 关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： 股东会召开日期：2026年1月23日 本次股东会采用的网络投票系统：上海证券交易所股东会网络 投票系统 一、召开会议的基本情况 网络投票起止时间：自2026 年 1 月 23 日 至2026 年 1 月 23 日 (一) 股东会类型和届次 2026年第一次临时股东会 (二) 股东会召集人：董事会 (三) 投票方式：本次股东会所采用的表决方式是现场投票和网 络投票相结合的方式 (四) 现场会议召开的日期、时间和地点 召开的日期时间：2026 年 1 月 23 日 10 点 00 分 召开地点：北京市朝阳区锐创国际中心 A 座 9 层会议室 (五) 网络投票的系统、起止日期和投票时间 网络投票系统：上海证券交易所股东会网络投票系统 采用上海证券交易所网络投票系统，通过交易系统投票平台的投 票时间为股东会召开当日的交易时间段， ...

华润双鹤公告，全资子公司北京万辉双鹤药业有限责任公司收到北京市药品监督管理局颁发的《药品 GMP符合性检查告知书》。检查范围为华润双鹤药业股份有限公司综合制造车间软胶囊剂生产线生产 软胶囊剂阿法骨化醇软胶囊。检查时间2025年11月26日至2025年11月28日，结论为符合《药品生产质量 管理规范(2010年修订)》和附录要求。该检查项目是在原有厂房、设备情况下的检查，未投入资金。 ...

证券代码：600062 证券简称：华润双鹤 公告编号：临 2026-001 华润双鹤药业股份有限公司 关于参与设立华润医药产业投资基金二期 完成基金备案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： | 投资标的名称 | 华润(成都)医药产业股权投资基金合伙企业(有限合 | | | | --- | --- | --- | --- | | | | 伙) | | | 投资金额(万元) | | 4,000 | | | 投资进展阶段 | √进展 | 完成 终止 | 交易要素变更 | | 特别风险提示 | 1、该基金采取分步出资方式，如各有限合伙人未能 | | | | | 按执行事务合伙人通知的金额和比例履行出资义 | | | | | 务，则可能影响基金的后续募集以及对外投资计划 | | | | | 的实施； | | | | | 2、基金具有投资周期长、流动性较低的特点，在投 | | | | | 资运作过程中将受到宏观经济、行业周期、政策法 | | | | | 规等多种因素影响，可能面临投资收益不达预期甚 ...

Group 1 - The establishment of the "China Resources Double Crane Biopharmaceutical Industry Fund" with a scale of 500 million yuan focuses on key technologies and high-tech achievement transformation projects in synthetic biology and related fields [1] - This fund is the first industry fund of China Resources Group dedicated to synthetic biology, aligning with the group's strategic initiative in emerging industries [1][3] - The company aims to create a second growth curve through synthetic biology, promoting significant development during the 14th Five-Year Plan period [1][3] Group 2 - China Resources Double Crane has over 80 years of experience in the pharmaceutical industry and operates 24 subsidiaries with approximately 13,000 employees, achieving annual sales exceeding 10 billion yuan [3] - The company has set two strategic goals for the 14th Five-Year Plan: to establish its core chemical drug business as "China's leading prescription drug brand" and to leverage synthetic biology technology for new growth [3] - The company’s subsidiary, Shenzhou Biotechnology, is a key platform for the industrialization of synthetic biology, with its core product, coenzyme Q10, holding the second-largest global market share [3] Group 3 - Synthetic biology is leading a global biotechnological revolution with vast market potential across various sectors, including food, healthcare, biomaterials, green agriculture, and personal care [4] - The fund will complement the company's external mergers and acquisitions, facilitating early-stage project innovation and integration with invested companies in technology, production, and market aspects [4] - The collaboration between China Resources Double Crane and the Hohhot municipal government will enhance the competitiveness of the synthetic biology industry, leveraging local resource advantages for large-scale fermentation production [4]

| | | | | | | | | | 中区:城 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 姓名 | 职务 | 性 别 | र्स 任期起始日期 任期终止日期 龄 | | 年初持 | 年末持 | 年度内 股份增 | 增减变 | 报告期内 从公司获 得的税前 | 是否在 公司关 | | | | | | | 股数 | 股数 | 成变动 重 | 动原因 | 报酬总额 (力元) | 联方获 取扱院 | | 陆文留 | 重事长 | 男 | 48 2023年9月21日 2027年7月10日 | | 247,600 | 247,600 | | | 270.06 | 是 | | 白晓松 | 重事 | 男 | 53 2022年3月2日 | 2027年7月10日 | 11 | - | | | 0.00 | 是 | | 赵 襄 | 東北 | 男 | 2024年11月12日 2027年7月10日 43 | | | 1 | | | 15.03 | 否 | | | 总裁 | | 2024年10月25日 2027年7月10日 | | ...

Group 1 - China Medical plans to acquire 70% equity of Zezheng Pharmaceutical for 525 million yuan to enhance its R&D capabilities in the pharmaceutical sector [1] - Hongchang Electronics has commenced production of its functional high-end copper-clad laminate electronic materials project [2] - China State Construction has secured multiple major projects totaling 32.09 billion yuan, which represents 1.5% of its audited revenue for 2024 [3] Group 2 - China Resources Double Crane has established an industrial fund with a committed investment of 83 million yuan, targeting a total fundraising goal of 500 million yuan [4] - Pinggao Electric and its subsidiaries have won state grid procurement projects worth approximately 876 million yuan, accounting for 7.06% of its 2024 revenue [5] - Dong'an Power received a government subsidy of 2.47 million yuan, with 1.47 million yuan related to assets and 1 million yuan related to income [6] Group 3 - Nantian Information has paid overdue taxes and penalties totaling 50.31 million yuan, which will impact its net profit for 2025 [7] - Erli Six has changed its investment plan to establish a wholly-owned subsidiary in Hong Kong for submarine cable business with an investment of 320 million yuan [8] - Dream Lily plans to invest 170 million yuan in an e-commerce warehouse project at its East US factory [9] Group 4 - Shen Shen Fang A's controlling shareholder has terminated the agreement to transfer 7.07% of the company's shares to Dongfang Asset, with no change in control [10] - Tianfu Culture has signed strategic cooperation framework agreements with various cultural and tourism bureaus to promote film and tourism integration [11] - Jinzi Tianzheng's chairman has resigned due to work adjustments, but will continue to fulfill his duties until a new chairman is elected [12] Group 5 - Jiangshan Oupai and its subsidiaries received government subsidies totaling 10.04 million yuan, with 7.51 million yuan related to income [13] - Ninghu Expressway plans to increase its investment in Jiangsu Danjin Expressway Co., Ltd. by 128 million yuan to support highway construction [14] - Jiangyin Bank has received approval for the qualifications of its employee director and vice president [15] Group 6 - Aoxiang Pharmaceutical has received approval for the listing application of two chemical raw materials [16] - Daye Co. has not yet commenced mass production of its robotic tendon products, with ongoing uncertainties in technology and profitability [17] - Rongsheng Environmental has proposed a cash dividend of 3.8 yuan per 10 shares, totaling approximately 97.36 million yuan [19] Group 7 - Yunyi Electric plans to invest 66 million USD in Morocco to establish a wholly-owned subsidiary and production base [20] - Derun Electronics has reached an agreement regarding the delayed payment of 100 million yuan in equity transfer funds [21] - Baihua Pharmaceutical is planning a change in control, leading to a continued suspension of its stock [22] Group 8 - CITIC Bank's executive director and president has resigned due to work adjustments [23] - Haizike's subsidiary has received acceptance for clinical trial applications for two innovative drugs [24] - Tianrun Dairy's subsidiaries received government subsidies totaling 21.53 million yuan, representing 49.32% of its net profit for 2024 [25] Group 9 - Andisou plans to issue 398 million A-shares at 7.54 yuan per share, raising a total of 3 billion yuan [26][27] - Fuda Co. has completed the transfer of its 50% stake in a joint venture, which is expected to positively impact its 2025 financial results [28] - Jianghua Micro has received environmental approval for a project to produce 37,000 tons of ultra-pure wet electronic chemicals [29] Group 10 - Nanwang Technology received a government subsidy of 10 million yuan, accounting for 0.66% of its net assets for 2024 [30] - Changgao Electric New has won state grid procurement projects totaling 161 million yuan, representing 9.14% of its 2024 revenue [31] - Huaxin Precision plans to invest up to 600 million yuan of idle funds in low-risk financial products [32] Group 11 - Fuguang Co. received a government subsidy of 1.26 million yuan for basic research projects, which is 13.27% of its net profit for 2024 [33] - Benli Technology has obtained a drug production license, which will help optimize its product structure [34] - Jintuo Co. proposed a cash dividend of 4.1 yuan per 10 shares, totaling approximately 99.48 million yuan [35] Group 12 - Kang Enbei has elected a new chairman and vice chairman during its board meeting [36] - Sanyuan Bio has completed the construction and installation of equipment for the remaining capacity of its 20,000-ton alulose project [38]

证券代码：600062 证券简称：华润双鹤 公告编号：临 2025-119 华润双鹤药业股份有限公司 关于设立华润双鹤产业基金完成基金备案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： 华润双鹤药业股份有限公司(以下简称"华润双鹤"或"公司")认缴 出资 8,300 万元参与投资设立华润双鹤生物医药产业基金投资(呼和 浩特)合伙企业(有限合伙)(以下简称"华润双鹤产业基金")，基金目标 募集规模为 5 亿元人民币。具体情况详见公司分别于 2025 年 8 月 13 日、10 月 30 日披露的《关于设立华润双鹤产业基金暨关联交易的公 告》(公告编号：临 2025-065)、《关于设立华润双鹤产业基金暨关联 交易的进展公告》(公告编号：临 2025-095)。 二、本次对外投资进展情况 近日，华润双鹤产业基金已在中国证券投资基金业协会完成备案 手续，备案信息如下： 基金名称：华润双鹤生物医药产业基金投资(呼和浩特)合伙企业 (有限合伙) 备案编码：SBML96 | 投资标的名称 | 华润双鹤生物医药产业 ...

Group 1 - The core announcement is that China Resources Double Crane has completed the filing procedures for its industrial fund with the Asset Management Association of China [1] - The company has committed to invest 83 million yuan in the establishment of the China Resources Double Crane Biopharmaceutical Industry Fund Investment (Hohhot) Partnership (Limited Partnership) [1] - The target fundraising scale for the fund is set at 500 million yuan [1]

证券日报网讯 12月29日，华润双鹤发布公告称，近日，公司全资子公司上海长征富民金山制药有限公 司收到了国家药品监督管理局颁发的低钙腹膜透析液（碳酸氢盐-G1.5%）、低钙腹膜透析液（碳酸氢 盐-G2.5%）[简称"低钙腹膜透析液（碳酸氢盐）系列药品"]，腹膜透析液（碳酸氢盐-G1.5%）、腹膜透 析液（碳酸氢盐-G2.5%）[简称"腹膜透析液（碳酸氢盐）系列药品"]《药品注册证书》。 （文章来源：证券日报） ...

Group 1 - The core point of the article is that China Resources Double Crane has received drug registration certificates for low-calcium peritoneal dialysis solutions from the National Medical Products Administration [1] - China Resources Double Crane's subsidiary, Shanghai Changzheng Fumin Jinshan Pharmaceutical Co., Ltd., is responsible for the newly approved products [1] - As of the report, China Resources Double Crane has a market capitalization of 19.1 billion yuan [1] Group 2 - For the first half of 2025, the revenue composition of China Resources Double Crane is as follows: non-infusion products account for 75.13%, infusion products account for 25.98%, and inter-segment eliminations account for -1.11% [1]